Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus Erythematosus
Open Access
- 29 July 2013
- journal article
- review article
- Published by Hindawi Limited in Clinical and Developmental Immunology
- Vol. 2013, 1-12
- https://doi.org/10.1155/2013/245928
Abstract
System lupus erythematosus (SLE) is an immune-complex-mediated autoimmune condition with protean immunological and clinical manifestation. While SLE has classically been advocated as a B-cell or T-cell disease, it is unlikely that a particular cell type is more pathologically predominant than the others. Indeed, SLE is characterized by an orchestrated interplay amongst different types of immunopathologically important cells participating in both innate and adaptive immunity including the dendritic cells, macrophages, neutrophils and lymphocytes, as well as traditional nonimmune cells such as endothelial, epithelial, and renal tubular cells. Amongst the antigen-presenting cells and lymphocytes, and between lymphocytes, the costimulatory pathways which involve mutual exchange of information and signalling play an essential role in initiating, perpetuating, and, eventually, attenuating the proinflammatory immune response. In this review, advances in the knowledge of established costimulatory pathways such as CD28/CTLA-4-CD80/86, ICOS-B7RP1, CD70-CD27, OX40-OX40L, and CD137-CD137L as well as their potential roles involved in the pathophysiology of SLE will be discussed. Attempts to target these costimulatory pathways therapeutically will pave more potential treatment avenues for patients with SLE. Preliminary laboratory and clinical evidence of the potential therapeutic value of manipulating these costimulatory pathways in SLE will also be discussed in this review.Keywords
This publication has 84 references indexed in Scilit:
- Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trialAnnals Of The Rheumatic Diseases, 2012
- Basis of CTLA-4 function in regulatory and conventional CD4+ T cellsBlood, 2012
- Pathogenesis of systemic lupus erythematosus revisited 2011: End organ resistance to damage, autoantibody initiation and diversification, and HLA-DRJournal of Autoimmunity, 2011
- Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 familyImmunological Reviews, 2011
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)Annual Review of Immunology, 2010
- Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosusArthritis Research & Therapy, 2010
- T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosusClinical Immunology, 2009
- Role of endogenous 4‐1BB in the development of systemic lupus erythematosusImmunology, 2007
- OX40 ligand shuts down IL-10-producing regulatory T cellsProceedings of the National Academy of Sciences, 2006
- CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosusClinical and Experimental Immunology, 2006